hydroxychloroquine
-
Why hydroxychloroquine’s appeal endures despite evidence it doesn’t work for Covid-19
The drug has consistently failed to show a benefit when tested in randomized, controlled clinical trials. Social science may explain why laypeople and doctors alike continue clinging to it.
-
Hydroxychloroquine flunks Phase III trial in mild-to-moderate Covid-19
The study adds to the growing body of evidence that the drug, promoted early in the pandemic by President Trump, is ineffective, despite its getting a briefly renewed lease on life earlier this month thanks to a retrospective analysis.
-
Do you advise self-insured employers? You Can Help Us!
Take part in this survey and share some of the trends you are seeing among your clients across healthcare, including chronic conditions, behavioral health and navigation.
-
Novartis halts its trial of hydroxychloroquine in Covid-19, citing poor enrollment
The drugmaker said an “acute” recruitment challenge made it unlikely the trial would be able to collect meaningful data on efficacy. More than a dozen hydroxychloroquine or chloroquine trials on ClinicalTrials.gov have been suspended, terminated or withdrawn.
-
FDA revokes emergency use authorization for hydroxychloroquine in Covid-19
The agency said its own analysis of the EUA, issued in March, and emerging data showed the drug and a related compound, chloroquine, were unlikely to be effective. The Trump administration had aggressively promoted the drug despite a lack of supporting scientific evidence.
-
Study that raised safety concerns about hydroxychloroquine in Covid-19 retracted
The study authors cited concerns about the veracity of data used in their analysis. The study, published last month, led the WHO to halt enrollment into the hydroxychloroquine arm of a clinical trial, while the French government revoked its authorization of the drug.
-
Randomized trial shows hydroxychloroquine doesn’t prevent Covid-19 as questions arise about earlier study
A randomized, placebo-controlled trial published in NEJM found the malaria drug was not effective as a post-exposure prophylaxis against coronavirus disease. However, questions have arisen about data used in a large observational study about the drug published last month.
-
Pas plus: France yanks authorization for hydroxychloroquine in Covid-19
According to a news report, the decision comes after French health authorities warned against the drug’s use. Meanwhile, the WHO suspended clinical testing of the drug after a paper in The Lancet raised concerns over safety and lack of efficacy.
-
Trump’s hydroxychloroquine remarks drive renewed interest in drug as 96,000-patient analysis finds no Covid-19 benefit
The study, published in The Lancet, found a possible association between hydroxychloroquine and chloroquine and heart arrhythmias and death. Meanwhile, SingleCare saw a as much as a 22% increase in scripts filled for hydroxychloroquine following Trump’s remarks last week.
-
Report: VA still using hydroxychloroquine for Covid-19; mounting data indicate no effect
The Associated Press nevertheless reported that fewer patients were using hydroxychloroquine than before. Meanwhile, two large studies from hospitals in the New York City area indicated that the drug did not improve rates of mortality among hospitalized patients.
-
Trayt Health Seeks to Increase Access to Diagnoses and Treatments
CEO Malekeh Amini explains how Trayt Health can bridge the gap for patients seeking neurological care.
-
Large study finds no benefit from hydroxychloroquine in Covid-19
The study, published Thursday in the New England Journal of Medicine, included 1,376 patients at a hospital in New York. However, it was an observational study rather than a randomized, controlled one.
-
FDA advises against use of hydroxychloroquine for Covid-19 outside hospitals, clinical trials
The FDA said patients should not use the drugs outside of hospital settings or clinical trials after a review of literature and data from poison control centers and its adverse event reporting system found instances of heart arrhythmias, some of which were fatal.
-
Trump’s favorite drug for Covid-19 smacked down in VA study, NIH guidance
A preprint retrospective analysis among 368 patients hospitalized with Covid-19 in the VA system found no benefit and a higher degree of death from hydroxychloroquine. A panel of experts also recommended against using the drug with azithromycin outside of trials due to potential toxicity.
-
FDA authorization of malaria drugs for Covid-19 risks undermining faith in agency, doctors write
In an opinion article in the New England Journal of Medicine, Drs. Benjamin Rome and Jerry Avorn of Harvard University wrote that advocating quick FDA approval for hydroxychloroquine and chloroquine despite paucity of evidence “runs counter to the idea of evidence-based medicine.”